Court Opinion

ID: 8374192
Source: CourtListenerOpinion
Date Created: 2022-10-18 21:01:54.34793+00
Date Added: 2024-06-11T16:46:16.118951
License: Public Domain

UNITED STATES DISTRICT COURT
                            FOR THE DISTRICT OF COLUMBIA

 THE INSTITUTE OF
 MULTIDIMENSIONAL MEDICINE,

         Plaintiff,

                v.                                      Civil Action No. 22-1308 (JEB)

 METAGENICS, INC.,

         Defendant.

                                  MEMORANDUM OPINION

       Amid the upheaval of the COVID-19 pandemic, businesses made changes to adapt to

new circumstances. In this suit, Plaintiff The Institute of Multidimensional Medicine (TIMM),

an integrative-healthcare practitioner’s office, contends that certain such changes implemented

by Defendant Metagenics, Inc., a supplier of healthcare products, breached their contract.

TIMM’s Complaint enumerated seven causes of action, which Metagenics now moves to

dismiss. Agreeing that each count is deficient, the Court will grant the Motion.

I.     Background

       At this stage, the Court must accept the facts as alleged in the Complaint as true, although

fortunately the parties here are in general agreement on the genesis of their partnership and the

causes of their disquietude. In 2011, Plaintiff, a two-person practitioner’s office, teamed up with

Defendant to sell the latter’s products — nutritional supplements and medical foods. See ECF

No. 16 (First Am. Compl.), ¶¶ 1, 26. At the time the agreement was struck, Defendant’s

products exhibited labels stating that they were “practitioner exclusive.” Id., ¶ 2. Plaintiff took

this to mean that “the product will only be distributed from a practitioner’s office.” Id. TIMM

claims that Metagenics’s policies and processes support this understanding. It alleges that

                                                 1
Defendant required TIMM “to provide medical license information” to purchase Metagenics

products, id., ¶ 8, and that individual customers were matched by Metagenics “to a local provider

for a medical recommendation.” Id., ¶ 9.

       For about nine years, all was hunky-dory. Enter COVID-19. During the pandemic, many

people rarely visited offices, including their doctors’ offices, in person. Apparently in response

to these changed circumstances, Defendant began to sell its products directly on Amazon. Id.,

¶¶ 11–12. It “did not notify practitioners” of this change in its practice, and it “continued to

advertise [its] products as practitioner exclusive.” Id., ¶ 12. Noting this change in business

practice, Plaintiff met with a Metagenics local representative on January 12, 2022, to discuss the

possibility of TIMM’s selling Metagenics products directly on Amazon as well. Id., ¶ 13. At

that January 12 meeting, Plaintiff was informed that if it were to sell Metagenics products on

Amazon, this would “not be an issue.” Id., ¶ 14. But on or around February 9, Defendant

canceled its contract with Plaintiff on the ground that TIMM’s distribution of Metagenics

products on Amazon violated Defendant’s policies and their contract. Id., ¶¶ 15, 17; see also

ECF No. 17 (Motion to Dismiss) at 3.

       In the Facts section of its Complaint, TIMM alleges that Metagenics’s unilateral

cancellation was a “violation of [its] contract with TIMM” and that this “hurt [Plaintiff’s]

reputation, and it jeopardized the continuity of care for [its] patients.” Id., ¶ 15. TIMM initially

filed in the Superior Court for the District of Columbia on April 8, 2022, but Metagenics

promptly removed the case here on the basis of diversity jurisdiction on May 12. See ECF No. 1

(Notice of Removal), ¶¶ 1, 5.

       Plaintiff’s First Amended Complaint, filed July 14, consists of seven causes of action that

are worthy of a first-year contracts syllabus. Count I alleges that Metagenics fraudulently

                                                  2
misrepresented that its products were “practitioner exclusive.” First Am. Compl., ¶ 26. In Count

II, Plaintiff alleges that Metagenics breached their contract. Id., ¶ 35. Count III alleges negligent

misrepresentation. Id., ¶ 49. Count IV alleges that Metagenics breached its duty of good faith

and fair dealing, id., ¶¶ 54–55, and Count V alleges unjust enrichment. Id., ¶¶ 60–61. Count VI

claims a breach of express and implied warranties of merchantability. Id., ¶¶ 65–73. Finally,

Count VII alleges that Metagenics breached its fiduciary duty to TIMM. Id., ¶¶ 88–90.

Defendant now moves to dismiss the Complaint in its entirety.

II.     Legal Standard

        Under Federal Rule of Civil Procedure 12(b)(6), a court must dismiss a claim for relief

when the complaint “fail[s] to state a claim upon which relief can be granted.” In evaluating a

motion to dismiss, the court must “treat the complaint’s factual allegations as true and must grant

plaintiff the benefit of all inferences that can be derived from the facts alleged.” Sparrow v.

United Air Lines, Inc., 216 F.3d 1111, 1113 (D.C. Cir. 2000) (internal quotation marks and

citation omitted); see also Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). A court need not accept

as true, however, “a legal conclusion couched as a factual allegation,” nor an inference

unsupported by the facts set forth in the complaint. Trudeau v. FTC, 456 F.3d 178, 193 (D.C.

Cir. 2006) (quoting Papasan v. Allain, 478 U.S. 265, 286 (1986)). Although “detailed factual

allegations” are not necessary to withstand a Rule 12(b)(6) motion, Bell Atl. Corp. v. Twombly,

550 U.S. 544, 555 (2007), “a complaint must contain sufficient factual matter, [if] accepted as

true, to state a claim to relief that is plausible on its face.” Iqbal, 556 U.S. at 678 (internal

quotation marks omitted). A plaintiff may survive a Rule 12(b)(6) motion even if “recovery is

very remote and unlikely,” but the facts alleged in the complaint “must be enough to raise a right

                                                   3
to relief above the speculative level.” Twombly, 550 U.S. at 555–56 (quoting Scheuer v.

Rhodes, 416 U.S. 232, 236 (1974)).

         A motion to dismiss under Rule 12(b)(6) must rely solely on matters within the

pleadings, see Fed. R. Civ. P. 12(d), which includes statements adopted by reference as well as

copies of written instruments joined as exhibits. See Fed. R. Civ. P. 10(c). Documents that a

defendant attaches to a motion to dismiss are “part of the pleadings” under Rule 10(c) if they are

integral to its claim, they are referred to in the complaint, and their authenticity is undisputed.

See Kaempe v. Myers, 367 F.3d 958, 965 (D.C. Cir. 2004); Hinton v. Corrs. Corp. of Am., 624

F. Supp. 2d 45, 46–47 (D.D.C. 2009). The court may thus consider those materials on a motion

to dismiss without treating the motion “as one for summary judgment under Rule 56.” Fed. R.

Civ. P. 12(d); Marshall v. Honeywell Tech. Solutions, Inc., 536 F. Supp. 2d 59, 65 (D.D.C.

2008).

III.     Analysis

         Metagenics has moved to dismiss all seven counts. For ease of analysis, the Court will

address some of the causes of action separately and some together.

         A. Counts I and III: Fraudulent and Negligent Misrepresentation

         Count I alleges that Defendant made fraudulent misrepresentations regarding its products

being “practitioner exclusive” because it now sells its products directly to consumers on Amazon

as well. See First Am. Compl., ¶¶ 26, 27. Count III alleges, in the alternative, that Defendant

was negligent in making such misrepresentations. Id., ¶¶ 48–49.

         The elements of the torts of fraudulent and negligent misrepresentation are similar. To

state a claim for the former under D.C. law, a plaintiff must allege: “(1) a false representation (2)

made in reference to a material fact, (3) with knowledge of its falsity, (4) with the intent to

                                                  4
deceive, and (5) an action that is taken in reliance upon the representation.” Hercules & Co.,

Ltd. v. Shama Restaurant Corp., 613 A.2d 916, 923 (D.C. 1992). For commercial entities

dealing with each other at arm’s length, any such reliance must also be (6) “objectively

reasonable.” Id. at 933. Finally, a plaintiff must also (7) “have suffered some injury as a

consequence of [its] reliance on the misrepresentation.” Chedick v. Nash, 151 F.3d 1077, 1081

(D.C. Cir. 1998) (citing Dresser v. Sunderland Apartments Tenants Ass’n, Inc., 465 A.2d 835,

839 (D.C. 1983)).

       To state a claim for negligent misrepresentation, conversely, a plaintiff is obliged to

allege the same elements, “except that they do not include the scienter requirements of a fraud

claim.” Parr v. Ebrahimian, 774 F. Supp. 2d 234, 240 (D.D.C. 2011). The plaintiff must instead

plead “that the defendant ‘made a false statement or omitted a fact that he had a duty to disclose,’

that the false statement or omission ‘involved a material issue,’ and that the plaintiff ‘reasonably

relied upon the false statement or omission to [his] detriment.’” Id. (quoting Redmond v. State

Farms Ins. Co., 728 A.2d 1202, 1207 (D.C. 1999)).

       A plaintiff, however, may not bring a claim for either fraudulent or negligent

misrepresentation when the basis for that claim is a breach of contract. Such a claim “must exist

in its own right independent of the contract, and any duty upon which the tort is based must flow

from considerations other than the contractual relationship.” Choharis v. State Farm Fire & Cas.

Co., 961 A.2d 1080, 1089 (D.C. 2008). In other words, “if one promises to pay another a given

sum of money by a named day, the contract creates a duty to pay; but a breach of that duty is not

a tort.’” Tate v. Aetna Cas. & Sur. Co., 253 S.E.2d 775, 777 (Ga. Ct. App. 1979).

       The Court finds that Counts I and III must be dismissed because the causes of action, as

alleged, cannot be separated from Plaintiff’s breach-of-contract claim in Count II. TIMM alleges

                                                 5
that it entered into a contractual agreement with Metagenics in 2011, at which time the products

were labeled as “practitioner exclusive,” and that it relied on Metagenics’s statements to that

effect. See First Am. Compl., ¶¶ 26, 29. Plaintiff also alleges that this label “tells” customers

that “the product will only be distributed from a practitioner’s office.” Id., ¶ 2. Plaintiff alleges

that this was a misrepresentation. Id., ¶ 27. These allegations make clear that the focus of both

Counts I and III is Metagenics’s alleged breach of the parties’ contract through the sale of its

own products on Amazon during the pandemic. But, as just explained, a plaintiff may not bring

a claim for misrepresentation when the basis is a breach of contract.

        Notwithstanding the above, a plaintiff may state a tort claim for fraud in the inducement

— that is, that she was tricked into entering an agreement on the basis of fraudulent

representations. Defendant acknowledges this: “‘[M]isrepresentations that precede the formation

of [a] contract and are alleged to have induced plaintiffs’ to enter into a contract are not

duplicative of a breach-of-contract claim.” MTD at 6. Here, however, all TIMM offers is the

strained suggestion that, at the time of the contract formation, it is somehow “plausible that

Metagenics knew that it was going to sell its products on Amazon” nine years later during a

global pandemic. See First Am. Compl., ¶ 31; see also ECF No. 20 (Pl. Opp.) at 5. As this

dubious assertion stands on its own with no supporting allegations, it does not clear the

plausibility bar. Nor can TIMM save its bacon by contending that “[d]iscovery will help

decipher Defendant’s intent when making the misrepresentations” in 2011. See First Am.

Compl., ¶ 31. One cannot plead a factually unsupported cause of action in the hopes of

uncovering helpful information in discovery. See Iqbal, 556 U.S. at 678 (complaint “must

contain sufficient factual matter, accepted as true, to state a claim to relief that is plausible on its

face”) (internal quotation marks and citation omitted). Finally, to the extent that Plaintiff

                                                   6
believes that Metagenics made actionable representations at the January 12, 2022 meeting, it

does not plead such representations as a basis for these counts.

       B. Counts II and IV: Breaches of Contract and Covenant

       Plaintiff’s second and fourth counts allege breach of contract and breach of the covenant

of good faith and fair dealing, respectively. See First Am. Compl., ¶¶ 35–39, 54–56. There are

four elements to a breach-of-contract claim in the District of Columbia: “[A] party must establish

(1) a valid contract between the parties; (2) an obligation or duty arising out of the contract; (3) a

breach of that duty; and (4) damages caused by breach.” Brown v. Sessoms, 774 F.3d 1016,

1024 (D.C. Cir. 2014) (quoting Tsintolas Realty Co. v. Mendez, 984 A.2d 181, 187 (D.C. 2009)).

       Every contract, furthermore, is held to contain “an implied covenant that neither party

shall do anything which will have the effect of destroying or injuring the right of the other party

to receive the fruits of the contract.” Abdelrhman v. Ackerman, 76 A.3d 883, 891 (D.C. 2013)

(quoting Hais v. Smith, 547 A.2d 986, 987 (D.C. 1988)). While the “meaning of ‘good faith’

varies with context,” good-faith performance “emphasizes faithfulness to an agreed common

purpose and consistency with the justified expectations of the other party.” Wright v. Howard

Univ., 60 A.3d 749, 755 (D.C. 2013). This “prevents a party from evading the spirit of the

contract, willfully rendering imperfect performance or interfering with the other party’s

performance.” Hais, 547 A.2d at 987–88 (D.C. 1988). Acting in such a manner may subject a

party to independent liability. See, e.g., Paul v. Howard Univ., 754 A.2d 297, 310 (D.C. 2000).

       Metagenics raises a number of challenges to these counts, but as regards Count II, the

Court focuses on one in particular — namely, that Plaintiff’s Complaint fails to identify a

provision of the contract that Defendant violated. More specifically, all TIMM alleges is a

general “fail[ure] to adhere to the direct terms of [Metagenics’s] agreement” with TIMM “as

                                                  7
outlined” in Defendant’s promotional materials and new account form. See First Am. Compl.,

¶ 35. The latter includes an “Internet Policy” that addresses sales of Metagenics products on

third-party sites. Id., ¶ 16; ECF 14-2, Exh. B (Internet Policy) at 4. Yet, TIMM never says how

these materials are part of its contract with Defendant. Even assuming, moreover, that the

contract somehow incorporates the Internet Policy, such policy would still be of no help to

Plaintiff. The policy explains that it is customers, not Defendant, who are prohibited from

selling Metagenics products on third-party platforms. See Internet Policy at 4.

       Perhaps seeing the handwriting on the wall, TIMM argues in its Opposition that the

breach-of-contract claim also includes an allegation that Metagenics breached a separate portion

of its Internet Policy, which requires 10 days’ notice before cancellation of an account. See Opp.

at 8; see also First Am. Compl., ¶¶ 16–17. But this allegation is included only in the general

Facts section of the Complaint and is not actually alleged in Count II. The Court will thus

dismiss this count without prejudice.

       The same problem of factual deficiency plagues Plaintiff’s claim for breach of the

implied covenant of good faith and fair dealing in Count IV. Just as TIMM has not alleged facts

to show that Metagenics made actionable misrepresentations or breached its contract, it has

similarly not sufficiently pled that Defendant has “evad[ed] the spirit of the contract, willfully

render[ed] imperfect performance or interfer[ed] with the other party’s performance.” Hais, 547

A.2d at 987–88. This count meets the same fate.

       C. Count V: Unjust Enrichment

       Next up is unjust enrichment. This count goes nowhere because, as a general rule,

allegations of an express contract warrant “dismissal of an unjust enrichment claim at the

motion-to-dismiss stage.” United States ex rel. Purcell v. MWI Corp., 254 F. Supp. 2d 69, 79

                                                  8
(D.D.C. 2003); see also Intelect Corp. v. Cellco Partnership GP, 160 F. Supp. 3d 157, 190

(D.D.C. 2016) (explaining that “in order to claim a remedy for unjust enrichment, there must be

no contract — either express or implied”). Plaintiff argues in its Opposition that unjust

enrichment can be pled in the alternative. See Opp. at 10. But this is only possible when such an

allegation is “supported by, at the very least, an allegation that there is no valid contract.” United

States ex rel Morsell v. Symantec Corp., 130 F. Supp. 3d 106, 129 (D.D.C. 2015). Because no

such allegation is made here, the Court will dismiss this count.

       D. Count VI: Breach of Warranties

       Count VI alleges a breach of both an express warranty and the implied warranty of

merchantability on the ground that Metagenics’s products were sold on Amazon, in alleged

contradiction of the product labels advertising that they were “practitioner exclusive.” First Am.

Compl., ¶¶ 66–70.

       Alleging a breach of either express or implied warranty requires a plaintiff to show “not

only the existence of the warranty but the fact that the warranty was broken and that the breach

of the warranty was the proximate cause of the loss sustained.” D.C. Code § 28:2-314 cmt. 13;

see also id., § 28:2-313. Defendant notes that the D.C. Uniform Commercial Code does not

provide a definition of “warranty,” MTD at 13, but both parties are in agreement that the

definition offered by Plaintiff in its Complaint is widely accepted: “a statement or representation,

made by a seller of goods as a part of a contract of sale, concerning the character, quality, or title

of goods.” Id. (quoting First Am. Compl., ¶ 65) (emphasis added).

       TIMM alleges that the “practitioner exclusive” label was a warranty, and that this was

breached when Metagenics began selling its products on Amazon. The Court cannot agree

because the manner of the sale of a product does not go to its “character, quality, or title.”

                                                  9
Defendant lists a congeries of cases in its Motion that are illustrative of situations where

warranties appropriately apply, see MTD at 13, and it correctly notes that warranties do not go to

the manner of sale of a product, but rather to the “quality, quantity, capacity, condition (or)

fitness of property for the purposes for which it is sold.” Enterprise-Laredo Assocs. v. Hachar’s,

Inc., 839 S.W. 2d 822, 831 (Tex. App. 1992) (internal quotation marks and citation omitted); see

also Picker X-Ray Corp. v. General Motors Corp., 185 A.2d 919, 921 (D.C. 1962) (explaining

that “a warranty is a duty imposed by law for the protection of the buying public” so as to protect

“innocent consumers from unexpected injuries or . . . defective products”). None of these

attributes — that is, the “character, quality, or title” of the goods — changes when the manner of

the sale of the good changes.

       Another independent ground requires dismissal. The D.C. Code clearly states that a

plaintiff must not only satisfy the elements of a breach-of-warranty claim as discussed above, but

that he must also notify the seller “within a reasonable time after he discovers or should have

discovered any breach” or “be barred from any remedy.” D.C. Code § 28:2-607(3)(a). Plaintiff

does not plausibly contend that it notified Metagenics within a reasonable time upon discovery of

such a breach and does not contest Defendant’s argument that it failed to do so until after

Plaintiff’s account had been canceled and there was no agreement in effect. See Opp. at 11–12;

MTD at 15. As a result, the Court finds that TIMM has not plausibly alleged that it satisfied the

D.C. Code’s notice requirement. For the aforementioned reasons, the Court grants dismissal of

Count VI.

       E. Count VII: Breach of Fiduciary Duty

       The final count challenged here is breach of fiduciary duty. “The mere existence of a

contractual relationship is ordinarily insufficient to give rise to a fiduciary duty.” Steele v.

                                                  10
Isikoff, 130 F. Supp. 2d 23, 36 (D.D.C. 2000) (citing Church of Scientology Int’l v. Eli Lilly &

Co., 848 F. Supp. 1018, 1028 (D.D.C. 1994)); see also Paul v. Judicial Watch, Inc., 543 F. Supp.

2d 1, 6 (D.D.C. 2008). In order to find that a fiduciary relationship has been established, one

characteristic that “District of Columbia courts have traditionally looked for is a ‘special

confidential relationship’ that transcends an ordinary business transaction.” High v. McLean

Fin. Corp., 659 F. Supp. 1561, 1568 (D.D.C. 1987).

       Plaintiff here alleges that the two parties had a relationship that “extended beyond the

limit[s] of their contractual relationship to a relationship founded on trust and confidence,” and

that this was breached when Defendant sold its products on Amazon. See First Am. Compl.,

¶¶ 80, 90. The Complaint further states that “TIMM trusted Metagenics to deliver quality

medical grade products for its customers,” that the parties “had a long-standing business

relationship,” and that Defendant “entitled the relationship ‘practitioner partnerships.’” Id.,

¶¶ 80, 81, 87. None of these conclusory allegations suffices to show that the two parties had a

relationship that extended beyond what is normal between standard commercial entities. See

Sandza v. Barclays Bank PLC, 151 F. Supp. 3d 94, 107 (D.D.C. 2015) (holding there is no

breach of fiduciary duty where plaintiff “does not plead any specific facts that suggest something

more than a standard, arms-length debtor-creditor relationship”).

       Count VII thus also goes by the board.

                                                 11
IV.    Conclusion

       For the foregoing reasons, the Court will issue a contemporaneous Order granting

Defendant’s Motion to Dismiss without prejudice.

                                                          /s/ James E. Boasberg
                                                          JAMES E. BOASBERG
                                                          United States District Judge
Date: October 18, 2022

                                              12